Adjuvant therapy after treatment of hepatocellular carcinoma

Japanese Journal of Gastroenterology

Volumn 105, Issue 6, 2008, Pages 787-794

  Kasai, Kazuhiro ^b   Kuroda, Hidekatsu ^b   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BRANCHED CHAIN AMINO ACID; CHLOROTRIANISENE; DNA; INTERFERON; MENAQUINONE; PHYTOMENADIONE; RETINOID X RECEPTOR; VIRUS RNA; 3,7,11,15-TETRAMETHYL-2,4,6,10,14-HEXADECAPENTAENOIC ACID; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; LAMIVUDINE; POLYPRENOIC ACID; RETINOIC ACID; VITAMIN K GROUP;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CELL CARCINOMA; LIVER RESECTION; RANDOMIZED CONTROLLED TRIAL; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; DIABETES MELLITUS; LIVER TUMOR; OBESITY; REVIEW; RISK FACTOR; TUMOR RECURRENCE;

AMINO ACIDS, BRANCHED-CHAIN; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERONS; LAMIVUDINE; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRETINOIN; VITAMIN K;

EID: 49049092900     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Takenaka K, Yamamoto K, Taketomi A, et al: A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 22;20-24:1995
2. Miyagawa S, Kawasaki S, Makuuchi M: Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 24;307-310:1996
3. Kumada T, Nakano S, Takeda I, et al: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25;87-92:1997
4. Kubo S, Kinoshita H, Hirohashi K, et al: Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation. Hepatogastroenterology 46;3212-3215:1999
5. Kubo S, Nishiguchi S, Shuto T, et al: Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 90;162-170:1999
6. Kubo S, Hirohashi K, Tanaka K, et al: Risk factors for recurrence after resection of hepatitis C virusrelated hepatocellular carcinoma. World J Surg 24;157-165:2000
7. Kubo S, Tanaka K, Shuto T, et al: Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol 40;972-979:2005
8. Muto Y, Moriwaki H, Ninomiya M, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334;1561-1567:1996
9. Muto Y, Moriwaki H, Saito A, et al: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340;1046-1047:1999
10. Mizuta T, Ozaki I, Eguchi Y, et al: The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106;867-872:2006
11. Muto Y, Sato S, Watanabe A, et al: Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35;204-214:2006
12. Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 356(9232);802-807:2000
13. Yoshiji H, Kuriyama S, Kawata M, et al: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7;1073-1078: 2001
14. Hasegawa K, Takayama T, Ijichi M, et al: Uraciltegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 44;891-895:2006
15. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328;1797-1801:1993
16. Yamamoto J, Kosuge T, Takayama T, et al: Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83;1219-1222:1996
17. Kubo S, Nishiguchi S, Hirohashi K, et al: High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepatogastroenterology 46;357-359:1999
18. Kubo S, Yamamoto T, Ikebe T, et al: Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Jpn J Cancer Res 90;1076-1080:1999
19. Nishiguchi S, Kuroki T, Nakatani S, et al: Randomised trial of effects of interferon-alpha on the incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346;1051-1055:1995
20. Shiratori Y, Imazeki F, Moriyama M, et al: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132;517-524:2000
21. Yano H, Iemura A, Haramaki M, et al: Interferon alia receptor expression and growth inhibition by interferon alia in human liver cancer cell lines. Hepatology 29;1708-1717:1999
22. Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32;228-232:2000
23. Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134;963-967:2001
24. Shiratori Y, Shiina S, Teratani T, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138;299-306:2003
25. Mazzaferro V, Romito R, Schiavo M, et al: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44;1543-1554:2006
26. Lin CL, Chen JD, Liu CJ, et al: Clinicopathological differences between hepatitis B viral genotype B-and C-related resectable hepatocellular carcinoma. J Viral Hepat 14;64-69:2007
27. Orito E, Sugauchi F, Tanaka Y, et al: Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 48;239-245:2005
28. Dienstag JL. Schiff ER, Wright TL, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341;1256-1263:1999
29. Liaw YF, Sung JJ, Chow WC, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351;1521-1531:2004
30. Matsumoto A, Tanaka E, Rokuhara A, et al: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 32;173-184:2005
31. Kubo S, Tanaka H, Takemura S, et al: Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 37;94-100:2007
32. Kuzuya T, Katano Y, Kumada T, et al: Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 22;1929-1935:2007
33. Altucci L, Gronemeyer H: The promise of retinoids to fight against cancer. Nat Rev Cancer 1;181-193:2001
34. Araki H, Shidoji Y, Yamada Y, et al: Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun 209;66-72:1995
35. Matsushima-Nishiwaki R, Okuno M, Takano Y, et al: Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24;1353-1359:2003
36. Moriwaki H, Yasuda I, Shiratori Y, et al: Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 3;727-731:1997
37. Chlebowski RT, Dietrich M, Akman S, et al: Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep 69;527-532:1985
38. Nutter LM, Cheng AL, Hung HL, et al: Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol 41;1283-1292:1991
39. Sakai I, Hashimoto S, Yoda M, et al: Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun 205;1305-1310:1994
40. Wang Z, Wang M, Finn F, et al: The growth inhibitory effects of vitamin K and their actions on gene expression. Hepatology 22;876-882:1995
41. Bouzahzah B, Nishikawa Y, Simon D, et al: Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. J Cell Physiol 165;459-467:1995
42. Orimo H, Shiraki M, Tomita A, et al: Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab 16;106-112:1998
43. Poon RT, Yu WC, Fan ST, et al: Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 19;779-788:2004
44. Nishitani S, Takehana K, Fujitani S, et al: Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 288;G1292-1300:2005
45. Gabrilovich DI: Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther 4;452-458:2002
46. Shimizu K, Kuriyama H, Kjaergaard J, et al: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27;265-272:2004
47. Watts C: Dendritic cells spill the beans. Nat Cell Biol 1;152-154:1999
48. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392;86-89:1998
49. McIlroy D, Gregoire M: Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52;583-591:2003
50. Kumagi T, Akbar SM, Horiike N, et al: Increased survival and decreased tumor size due to intratumoral injection of ethanol followed by administration of immature dendritic cells. Int J Oncol 23;949-955:2003
51. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407;249-257:2000
52. Lever AF, Hole DJ, Gillis CR, et al: Do inhibitors of angiotensin-I -converting enzyme protect against risk of cancer? Lancet 352;179-184:1998
53. Lai EC, Lo CM, Fan ST, et al: Postoperative adjuvant chemotherapy after curative of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133;183-188:1998
54. Koga K: Clinical aspects of cryptogenic hepatocellular carcinoma. Kurume Med J 45;105-111:1998
55. Shimada M, Hashimoto E, Taniai M, et al: Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37;154-160:2002
56. Reid AE: Nonalcoholic steatohepatitis. Gastroenterology 121;710-723:2001
57. Powell EE, Cooksley WG, Hanson R, et al: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11;74-80:1990
58. Tarantino G, Conca P, Sorrentino P, et al: Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 21;1266-1268:2006
59. Pekow JR, Bhan AK, Zheng H, et al: Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109;2490-2496:2007